Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook

Key Takeaways Ionis posted a smaller-than-expected Q3 loss and a 17% year-over-year revenue increase.Commercial revenue jumped 53% YoY on strong Tryngolza sales and higher Wainua royalties.The company raised its 2025 revenue outlook to $875-$900 million, citing solid drug uptake.Ionis Pharmaceuticals (IONS) reported third-quarter 2025 adjusted loss per share of 61 cents, much narrower than the Zacks Consensus Estimate of a loss of $1.15. In the year-ago period, the company reported an adjusted loss of 72 ce ...